Cost and Allocation of Scarce CAR-T Therapy for Patients With Multiple Myeloma
Researchers sought to determine the allocation and cost involved with CAR-T therapy for patients with multiple myeloma.
Diagnosis & Disease Information
Higher Rate of Infections After AHCT for Multiple Myeloma Seen in India
Researchers sought to determine rates of infections for patients with multiple myeloma receiving autologous transplantation in India compared to other countries.
Carfilzomib- and Pomalidomide-Based Regimens May Not Improve Outcomes in MM After Daratumumab
Researchers sought to determine whether carfilzomib- or pomalidomide-based therapeutic regimens would improve survival in MM following daratumumab.
PET Imaging After ASCT Identified Residual Disease in MM
Researchers sought to determine whether screening patients with MM after ASCT with FDG-PET would be able to identify patients with residual disease.
Postoperative Complications Common After Spinal Surgery for Multiple Myeloma
Researchers evaluated data from 270 patients with MM undergoing spine surgery to determine complication and reoperation rates.
Vitamins C, D Supplementation Beneficial in Chemotherapy for Acute Myeloid Leukemia
Use of vitamin C and D supplementation evaluated for its efficacy for patients with AML undergoing intensive induction chemotherapy.
Aphexda Approved for Stem Cell Mobilization for ASCT in Multiple Myeloma
Aphexda is expected to be available in September 2023.
Global Incidence of Early-Onset Cancers Rose 80% From 1990 to 2019
New data suggest that, from 1990 to 2019, the global incidence of early-onset cancer increased by nearly 80%, and the rate of early-onset cancer deaths increased by nearly 30%.
Risk of Infections Higher With Bispecific Antibody Therapy for Multiple Myeloma
Researchers sought to assess and better characterize the risk of infection in patients with MM treated with bispecific antibodies.
CAR‑HEMATOTOX Score Shows Prognostic Utility for CAR‑T Therapy in Relapsed/Refractory Multiple Myeloma
Researchers sought to determine whether the CAR‑HEMATOTOX score would have prognostic value for both toxicity and treatment response in patients with R/R MM receiving CAR-T therapy.
- Loading...
Loading...
Next post in Multiple Myeloma
Loading... 
Loading...